Providing a new target decision date in tandem with missing a user fee review deadline would help FDA restore credibility and predictability to the review process, former FDA official Bruce Burlington suggests
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.
The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.
The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.
